A randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis.

CONCLUSIONS: Once-weekly injection of 20 units of elcatonin significantly increased lumbar BMD over a 3-year period and did not cause any safety problems, but no significant reduction in the incidence of vertebral or non-vertebral fractures was demonstrated. PMID: 29986611 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29986611?dopt=Abstract

Source: Current Medical Research and Opinion - July 11, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research